These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 35656636)

  • 61. An evaluation of talimogene laherparepvec for the treatment of melanoma.
    Broman KK; Zager JS
    Expert Opin Biol Ther; 2020 Jan; 20(1):9-14. PubMed ID: 31690129
    [No Abstract]   [Full Text] [Related]  

  • 62. Complete response to talimogene laherparepvec in a primary acral lentiginous melanoma.
    Franke V; Smeets PMG; van der Wal JE; van Akkooi ACJ
    Melanoma Res; 2020 Dec; 30(6):548-551. PubMed ID: 32516238
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Talimogene laherparepvec (T-Vec) for the treatment of melanoma and other cancers.
    Grigg C; Blake Z; Gartrell R; Sacher A; Taback B; Saenger Y
    Semin Oncol; 2016 Dec; 43(6):638-646. PubMed ID: 28061981
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Talimogene Laherparepvec in Advanced Mucosal Melanoma of the Urethra Upon Primary Resistance on Immune Checkpoint Inhibition: A Case Report.
    Fröhlich A; Hoffmann F; Niebel D; Egger E; Kukuk GM; Toma M; Sirokay J; Bieber T; Landsberg J
    Front Oncol; 2020; 10():611. PubMed ID: 32457834
    [No Abstract]   [Full Text] [Related]  

  • 65. Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma.
    Chesney J; Puzanov I; Collichio F; Milhem MM; Hauschild A; Chen L; Sharma A; Garbe C; Singh P; Mehnert JM
    Br J Cancer; 2019 Aug; 121(5):417-420. PubMed ID: 31353364
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Panniculitis in a patient with pathologic complete response to talimogene laherparepvec treatment for recurrent, in-transit melanoma.
    Long TH; Shinohara MM; Argenyi ZB; Thompson JA; Gardner JM
    J Cutan Pathol; 2018 Nov; 45(11):864-868. PubMed ID: 30054925
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma.
    Bommareddy PK; Patel A; Hossain S; Kaufman HL
    Am J Clin Dermatol; 2017 Feb; 18(1):1-15. PubMed ID: 27988837
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition.
    Blake Z; Marks DK; Gartrell RD; Hart T; Horton P; Cheng SK; Taback B; Horst BA; Saenger YM
    J Immunother Cancer; 2018 Apr; 6(1):25. PubMed ID: 29622046
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer.
    Kai M; Marx AN; Liu DD; Shen Y; Gao H; Reuben JM; Whitman G; Krishnamurthy S; Ross MI; Litton JK; Lim B; Ibrahim N; Kogawa T; Ueno NT
    Sci Rep; 2021 Nov; 11(1):22242. PubMed ID: 34782633
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Talimogene laherparepvec (T-VEC) as cancer immunotherapy.
    Kohlhapp FJ; Zloza A; Kaufman HL
    Drugs Today (Barc); 2015 Sep; 51(9):549-58. PubMed ID: 26488034
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Talimogene laherparepvec: overview, combination therapy and current practices.
    O'Donoghue C; Doepker MP; Zager JS
    Melanoma Manag; 2016 Dec; 3(4):267-272. PubMed ID: 30190898
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Final 5-Year Follow-Up Results Evaluating Neoadjuvant Talimogene Laherparepvec Plus Surgery in Advanced Melanoma: A Randomized Clinical Trial.
    Dummer R; Gyorki DE; Hyngstrom JR; Ning M; Lawrence T; Ross MI
    JAMA Oncol; 2023 Oct; 9(10):1457-1459. PubMed ID: 37561473
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma.
    Johnson DB; Puzanov I; Kelley MC
    Immunotherapy; 2015; 7(6):611-9. PubMed ID: 26098919
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Talimogene Laherparepvec for the Treatment of Advanced Melanoma.
    Ott PA; Hodi FS
    Clin Cancer Res; 2016 Jul; 22(13):3127-31. PubMed ID: 27146699
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study.
    Kaufman HL; Amatruda T; Reid T; Gonzalez R; Glaspy J; Whitman E; Harrington K; Nemunaitis J; Zloza A; Wolf M; Senzer NN
    J Immunother Cancer; 2016; 4():12. PubMed ID: 26981242
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A Phase I Trial of Talimogene Laherparepvec in Combination with Neoadjuvant Chemotherapy for the Treatment of Nonmetastatic Triple-Negative Breast Cancer.
    Soliman H; Hogue D; Han H; Mooney B; Costa R; Lee MC; Niell B; Williams A; Chau A; Falcon S; Khakpour N; Weinfurtner RJ; Hoover S; Kiluk J; Rosa M; Khong H; Czerniecki B
    Clin Cancer Res; 2021 Feb; 27(4):1012-1018. PubMed ID: 33219014
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Talimogene laherparepvec: review of its mechanism of action and clinical efficacy and safety.
    Raman SS; Hecht JR; Chan E
    Immunotherapy; 2019 Jun; 11(8):705-723. PubMed ID: 31045464
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Efficacy and safety of oncolytic viruses in advanced or metastatic cancer: a network meta-analysis.
    Xie R; Bi X; Shang B; Zhou A; Shi H; Shou J
    Virol J; 2021 Jul; 18(1):158. PubMed ID: 34332591
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Dermoscopy as response evaluation tool for cutaneous malignant melanoma metastases treated with Talimogene Laherparepvec: a prospective feasibility study.
    Stahlie EHA; van Akkooi ACJ; Plasmeijer E
    J Eur Acad Dermatol Venereol; 2022 Dec; 36(12):2373-2378. PubMed ID: 35920755
    [TBL] [Abstract][Full Text] [Related]  

  • 80. OrienX010, an oncolytic virus, in patients with unresectable stage IIIC-IV melanoma: a phase Ib study.
    Cui C; Wang X; Lian B; Ji Q; Zhou L; Chi Z; Si L; Sheng X; Kong Y; Yu J; Li S; Mao L; Tang B; Dai J; Yan X; Bai X; Andtbacka R; Guo J
    J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35383116
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.